Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Expenses (2016 - 2025)

Ultragenyx Pharmaceutical has reported Operating Expenses over the past 10 years, most recently at $320.6 million for Q4 2025.

  • Quarterly Operating Expenses rose 11.71% to $320.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 10.22% year-over-year, with the annual reading at $1.2 billion for FY2025, 10.22% up from the prior year.
  • Operating Expenses was $320.6 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $330.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $330.8 million in Q3 2025 and troughed at $169.8 million in Q2 2021.
  • The 5-year median for Operating Expenses is $255.4 million (2023), against an average of $252.6 million.
  • Year-over-year, Operating Expenses surged 84.15% in 2022 and then dropped 23.0% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $186.0 million in 2021, then surged by 33.89% to $249.0 million in 2022, then rose by 0.0% to $249.0 million in 2023, then increased by 15.25% to $287.0 million in 2024, then rose by 11.71% to $320.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Operating Expenses are $320.6 million (Q4 2025), $330.8 million (Q3 2025), and $274.4 million (Q2 2025).